EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

Jibran Ahmed, Filip Janku, Daniel D Karp, Sarina A Piha-Paul, Apostolia M Tsimberidou iD, Timothy Anthony Yap, Bettzy Stephen iD, Yali Yang, Serdar Gurses, Qian Liu, Juhee Song, Funda Meric-Bernstam iD und 1 weitere

Cancer · 2025-02 · 131 (3)

DOI: 10.1002/cncr.35728 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 23.01.2025. Verfasst von Jibran Ahmed und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carbamates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, BioXcel Therapeutics, National Institutes of Health/National Cancer Institute (NIH/NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket trial assessed the antitumor activity of combining talabostat and pembrolizumab (anti–programmed death‐1 antibody) in advanced solid tumor patients.

Methods

The primary objective was assessment of dose‐limiting toxicity (DLT) rates in the first six patients (lead‐in stage) and response rate (efficacy stage; included cohort A [checkpoint inhibitor (ICI) naive] and cohort B [ICI pretreated]) for the study treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST). Efficacy was assessed using a Bayesian optimal phase 2 design.

Results

A total of 31 patients enrolled in this trial (14 in cohort A, 17 in cohort B). The median age was 61 years; 17 (55%) patients were male and 21 (68%) patients were White. Among 19 (61%) patients evaluable for response, the best response was stable disease in nine patients, unconfirmed progressive disease in seven patients, and clinical progressive disease in three patients based on iRECIST. Disease control rate was 47%. One patient with programmed death‐ligand 1 negative, microsatellite stable endometrial cancer had unconfirmed partial response. Median progression‐free survival was 2.7 months; median overall survival was 20.5 months. One patient (cohort A) experienced a grade 4 hypotension as a DLT and treatment discontinuation. The most common toxicities were hypotension (22.6%), fatigue (9.7%), diarrhea, rash, thrombocytopenia, vomiting, syncope, general disorders and administration site conditions‐other, and skin and subcutaneous tissue disorders‐other, each in 6.5% of patients.

Conclusions

This study of the combination of talabostat and pembrolizumab in patients with advanced solid tumors demonstrated predictable adverse events and limited activity. The combination was shown to be safe. Efficacy data shows immune stable disease in nine of 19 evaluable patients, and an unconfirmed immune partial response in a patient with endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overResponse Evaluation Criteria in Solid Tumors

Stichwörter der Autor:innen

cancerimmunotherapypembrolizumabtalabostat

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabCarbamates

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Apostolia M Tsimberidou, Bettzy Stephen, Funda Meric-Bernstam, Aung Naing

Förderung

  • NCI NIH HHS
  • BioXcel Therapeutics
  • National Institutes of Health/National Cancer Institute (NIH/NCI)
  • National Institutes of Health

Zitieren

APA

Ahmed, J., Janku, F., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Yap, T. A., Stephen, B., Yang, Y., Gurses, S., Liu, Q., Song, J., Meric-Bernstam, F., & Naing, A. (2025). A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer, 131(3). https://doi.org/10.1002/cncr.35728

Vancouver

Ahmed J, Janku F, Karp DD, Piha-Paul SA, Tsimberidou AM, Yap TA, et al. A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer. 2025;131(3). doi:10.1002/cncr.35728

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Jibran and Janku, Filip and Karp, Daniel D and Piha-Paul, Sarina A and Tsimberidou, Apostolia M and Yap, Timothy Anthony and Stephen, Bettzy and Yang, Yali and Gurses, Serdar and Liu, Qian and Song, Juhee and Meric-Bernstam, Funda and Naing, Aung},
  title = {A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {3},
  doi = {10.1002/cncr.35728}
}
Kostenlos starten →